Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)

Next Previous
Trial Profile

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 13 Dec 2023 Number of treatment arms are decreased from 3 to 1 by the merger of 3 arms into 1, and Ipilimumab is removed from the treatments. Study design is changed from randomized, double blind, parallel to open label, non-randomized, single-group assignment.
  • 13 Dec 2023 Planned number of patients changed from 45 to 20.
  • 13 Dec 2023 Planned End Date changed from 1 Mar 2027 to 1 Mar 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top